Philadelphia, Pennsylvania — According to state and local economic development sources Spark Therapeutics plans to invest $575,000,000.00 to build out 500,000 square feet of new space in Philadelphia. The company plans to occupy the new space at 30th and Chestnut Street in Philadelphia, on or about October 1, 2024. According to the company website Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

To learn more about Spark Therapeutics, visit http://sparktx.com/

Company Contact:
Jeff Marrazzo, Chief Executive Officer
https://www.linkedin.com/in/jeffreydmarrazzo/
215-220-9300

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved